Tc99m-MAA

Phase 1Biologic

MMassachusetts General Hospital

Tc99m-MAA is one of 4 biologic programs targeting Hemoptysis. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HemoptysisActive, not recruiting

HemoptysisPhase 1

Active, not recruiting

Competition

Competitive Landscape

4 competitors in Hemoptysis

#DrugCompanyPhaseTrials

Adrenaline

SSamson Clinical Operations Pty Ltd

Cyklokapron

4 3

Glypressin

MMallinckrodt

Phase 3

1 4

Tc99m-MAA

MMassachusetts General Hospital

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hemoptysis1 trial

Tc99m-MAA Bronchial Artery Injection During Bronchial Embolization for Pulmonary Mass Induced Hemoptysis for Dosimetry Planning

Completed·MMassachusetts General Hospital·Phase 1·NCT04105283·8 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Tc99m-MAA. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Tc99m-MAA compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Tc99m-MAA. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Massachusetts General Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: MMassachusetts General Hospital

Tc99m-MAA

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Hemoptysis1 trial

References

Drug Info

Quick Facts

Related News